CBD

Medical Marijuana in the treatment of Multiple Sclerosis.
Post Reply
User avatar
Petr75
Family Elder
Posts: 1610
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

CBD

Post by Petr75 »

2020 Nov 9
Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea

Emerging potential of cannabidiol in reversing proteinopathies
https://pubmed.ncbi.nlm.nih.gov/33181336/

Abstract

The aberrant accumulation of disease-specific protein aggregates accompanying cognitive decline is a pathological hallmark of age-associated neurological disorders, also termed as proteinopathies, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis. Along with oxidative stress and neuroinflammation, disruption in protein homeostasis (proteostasis), a network that constitutes protein surveillance system, plays a pivotal role in the pathobiology of these dementia disorders. Cannabidiol (CBD), a non-psychotropic phytocannabinoid of Cannabis sativa, is known for its pleiotropic neuropharmacological effects on the central nervous system, including the ability to abate oxidative stress, neuroinflammation, and protein misfolding. Over the past years, compelling evidence has documented disease-modifying role of CBD in various preclinical and clinical models of neurological disorders, suggesting the potential therapeutic implications of CBD in these disorders. Because of its putative role in the proteostasis network in particular, CBD could be a potent modulator for reversing not only age-associated neurodegeneration but also other protein misfolding disorders. However, the current understanding is insufficient to underpin this proposition. In this review, we discuss the potentiality of CBD as a pharmacological modulator of the proteostasis network, highlighting its neuroprotective and aggregates clearing roles in the neurodegenerative disorders. We anticipate that the current effort will advance our knowledge on the implication of CBD in proteostasis network, opening up a new therapeutic window for aging proteinopathies.
https://www.eboro.cz
User avatar
NHE
Volunteer Moderator
Posts: 6221
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: CBD

Post by NHE »

Petr75 wrote: Sun Dec 06, 2020 7:42 am 2020 Nov 9
Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea
Emerging potential of cannabidiol in reversing proteinopathies
https://pubmed.ncbi.nlm.nih.gov/33181336/

Free full text. https://www.sciencedirect.com/science/a ... via%3Dihub
User avatar
Petr75
Family Elder
Posts: 1610
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: CBD

Post by Petr75 »

2021 Sep 6
Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
Treatment with Delta-9-tetrahydrocannabinol/cannabidiol in Multiple Sclerosis: Influence on the Autonomy Profile according to the International Classification of Functioning, Disability and Health
https://pubmed.ncbi.nlm.nih.gov/34671570/

Abstract

Multiple sclerosis (MS) is the most common cause of non-traumatic neurological disability in young adults. It has effects at different levels: physical, emotional, psychological, cognitive and social, with a great variety of signs and symptoms. In particular, spasticity contributes to reducing the motor performance of patients with MS, causing pain, reduction in distance walked and limitations in social life. We present the case of a 39-year-old woman with MS. She was treated with delta-9-tetrahydrocannabinol/cannabidiol and the outcome was assessed with the International Classification of Functioning Disability and Health core set framework.

Learning points: The clinical presentation of multiple sclerosis (MS) is heterogeneous but very often lower limb spasticity leads to severe disability.The use of nabiximols improved spasticity control and motor performance in walking, and also had a larger effect in improving activity and participation in personal relationships.Appropriate assessment of MS cases, through the ICF framework, may demonstrate further effects of nabiximols on patient capacity and performance.
https://www.eboro.cz
ArthurJ
Family Member
Posts: 70
Joined: Tue Dec 27, 2011 10:47 pm
Location: Third stone from the sun.

Re: CBD

Post by ArthurJ »

From the full paper...

https://www.ncbi.nlm.nih.gov/pmc/articl ... po=1.51515

"After 6 weeks of treatment with nabiximols, no adverse events were observed. At 12 weeks of treatment, screening scores were satisfactory (NRS: 3, VAS: 3, MoCA and DASS-21: normal) and the patient’s autonomy had also increased. She went out more often, managed to take trips with her husband, had paraglided, and had expanded her circle of friends."
Post Reply

Return to “Medical Marijuana”